Pamela Hackl, DO
Family Medicine · Temperance, MINPI 1134125024
Payments from drug & device makers
Across 856 payments — averaging $18.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Novo Nordisk$2K
- Corcept Therapeutics$2K
- Lilly USA, LLC$1K
- AstraZeneca$1K
- Amgen$1K
- plus $5K from 29 others
What the payments were for
- Speaking & faculty fees$1,62510%
- Food & beverage$13,81688%
- Education$1801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 110 | $3,165 |
| Novo Nordisk | 158 | $2,155 |
| Corcept Therapeutics | 64 | $1,503 |
| Lilly USA, LLC | 87 | $1,297 |
| AstraZeneca(2 entities) | 73 | $1,276 |
| Amgen | 62 | $1,015 |
| Boehringer Ingelheim | 38 | $667 |
| GSK | 39 | $587 |
| Pfizer | 41 | $582 |
| Teva Pharmaceuticals USA, Inc. | 32 | $573 |
| Kowa Pharmaceuticals America, Inc. | 24 | $345 |
| Amarin Pharma, Inc. | 18 | $304 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $199 |
| Biohaven Pharmaceuticals, Inc. | 10 | $179 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $166 |
| Novartis | 10 | $163 |
| Bayer | 7 | $150 |
| Johnson & Johnson | 9 | $149 |
| Sanofi-aventis U.S. LLC | 9 | $147 |
| Merck | 8 | $146 |
| Actelion Pharmaceuticals US, Inc. | 4 | $146 |
| Otsuka America Pharmaceutical, Inc. | 7 | $146 |
| Regeneron Healthcare Solutions, Inc. | 5 | $107 |
| AMAG Pharmaceuticals, Inc. | 2 | $83 |
| Exact Sciences | 4 | $79 |
| Esperion Therapeutics, Inc. | 3 | $70 |
| Dexcom, Inc. | 3 | $49 |
| Radius Health, Inc. | 3 | $46 |
| Boston Scientific | 1 | $27 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| VBI Vaccine (delaware) Inc. | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Bristol Myers Squibb | 1 | $17 |
| Alfasigma USA, Inc. | 1 | $13 |
| Valeritas, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,621 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StrensiqAsfotase Alfa | 27 | $2,218,364 |
| JardianceEmpagliflozin | 136 | $147,286 |
| FarxigaDapagliflozin Propanediol | 126 | $133,523 |
| OzempicSemaglutide | 77 | $105,620 |
| EliquisApixaban | 51 | $67,198 |
| TrulicityDulaglutide | 37 | $52,143 |
| ProliaDenosumab | 24 | $39,615 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $35,071 |
| Repatha SureclickEvolocumab | 41 | $32,664 |
| MounjaroTirzepatide | 25 | $32,611 |
| VascepaIcosapent Ethyl | 48 | $27,221 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $25,318 |
| GlyxambiEmpagliflozin/Linagliptin | 19 | $23,594 |
| XareltoRivaroxaban | 19 | $23,250 |
| Icosapent Ethyl | 51 | $22,681 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaStrensiq, Farxiga, Breztri Aerosphere | $1,276 | $2,368,524170 claims |
| Boehringer IngelheimJardiance, Glyxambi, Stiolto Respimat | $667 | $184,081172 claims |
| Novo NordiskOzempic | $2,155 | $105,62077 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,297 | $84,75462 claims |
| PfizerEliquis | $582 | $67,19851 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $587 | $55,19359 claims |
| AmgenProlia | $1,015 | $39,61524 claims |
| Johnson & JohnsonXarelto | $149 | $23,25019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Temperance
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.